Syndax Pharmaceuticals, Inc.

SNDX

NASDAQ

Healthcare

Biotechnology

New York City, MA, US270 employeessyndax.com

$25.08

+1.20(5.04%)

Mkt Cap $2.2B

$8.73

$25.15

52-Week Range

At A Glance

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.

Revenue is primarily driven by Net Product Revenues (67.6%) and Collaboration Revenue (21.6%).

Most recently: and in Exhibits 99.1 and 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange (2026-02-26).

$2.2B

Market Cap

$175M

Revenue

-$291M

Net Income

Employees270

Fundamentals

How The Business Makes Money

Revenue by Segment

Net Product Revenues67.6%($133M)

Collaboration Revenue21.6%($42M)

Milestone Revenue10.8%($21M)

Activity

What Changed Recently

Financial Results

Feb 25, 2026

and in Exhibits 99.1 and 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange

Financial Results

Jan 11, 2026

. Item 7.01 Regulation FD Disclosure. The disclosure in Item 2.02 above is hereby incorporated by reference into this Item 7.01. The information contained in It

Peer Companies

Company	Price	Change	Market Cap	P/E
RLAYRelay Therapeutics, Inc.	$12.56	+16.67%	$2.2B	-6.1
NKTRNektar Therapeutics	$77.01	+1.72%	$1.6B	-9.2
IMTXImmatics N.V.	$10.36	+3.45%	$1.4B	-5.5
AMLXAmylyx Pharmaceuticals, I...	$15.02	+4.66%	$1.2B	-8.8
CVACCVAC	$4.66	+0.00%	$1.0B	—
ZBIOZenas BioPharma, Inc.	$21.48	+5.50%	$959M	-2.5
INBXInhibrx Biosciences, Inc.	$63.59	-5.17%	$929M	-7.1
ORICORIC Pharmaceuticals, Inc...	$8.90	+19.06%	$893M	-7.5

Analyst View

Company Profile

CIK0001395937

ISINUS87164F1057

CUSIP87164F105

Phone781 419 1400

Address35 Gatehouse Drive, New York City, MA, 02451, US

SEC EDGAR